CDK4 and neoplasm: Combination treatment with an IGF-1R inhibitor and CDK4/6 inhibitor demonstrated synergistic activity by inhibiting tumor growth and survival of ES cells in vivo and in vitro through the suppression of PKC/AKT/mTOR and activation of RB (Guenther et al., 2019).